^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ERBB3 mutation

    i
    Other names: ERBB3, HER3, LCCS2, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3
    Entrez ID:
    2065
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis (NCT05828069)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    03/28/2024
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    BRAF • ALK • ERBB3
    |
    BRAF V600E • BRAF V600 • ERBB3 mutation
    |
    Ojemda (tovorafenib)
    Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer (NCT02673398)
    Phase 2
    City of Hope Medical Center
    Completed
    Last update posted :
    06/16/2023
    Initiation :
    12/02/2016
    Primary completion :
    03/12/2020
    Completion :
    09/22/2022
    ERBB3
    |
    HER-2 positive • HER-2 negative • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 L755P • ERBB3 mutation • HER-2 S310Y • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • ERBB3 V659E • HER-2 G778_S779insCPG • HER-2 L755_T759del • HER-2 A775 • HER-2 D769H • HER-2 R678Q • HER-2 R896C • HER-2 YVMA • ERBB3 L755S
    |
    Nerlynx (neratinib)
    Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression (NCT05512182)
    Phase 2
    Yonsei University
    Withdrawn
    Last update posted :
    06/15/2023
    Initiation :
    09/15/2022
    Primary completion :
    10/30/2023
    Completion :
    10/30/2023
    EGFR • HER-2 • ERBB3 • ERBB4
    |
    HER-2 positive • EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 negative • ERBB3 mutation • ERBB4 mutation
    |
    Keytruda (pembrolizumab) • paclitaxel • Nerlynx (neratinib)
    A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer (NCT05769764)
    Phase N/A
    Daiichi Sankyo, Inc.
    Completed
    Last update posted :
    04/10/2023
    Initiation :
    12/19/2022
    Primary completion :
    04/06/2023
    Completion :
    04/06/2023
    KRAS • ALK • ERBB3
    |
    KRAS mutation • EGFR mutation • KRAS G12C • EGFR exon 20 insertion • ERBB3 expression • KRAS G12 • EGFR exon 20 mutation • ERBB3 mutation
    Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy (LUX-Bladder 1) (NCT02780687)
    Phase 2
    Boehringer Ingelheim
    Completed
    Last update posted :
    11/18/2020
    Initiation :
    06/09/2016
    Primary completion :
    09/24/2018
    Completion :
    09/02/2019
    EGFR • HER-2 • ERBB3
    |
    HER-2 amplification • HER-2 mutation • EGFR amplification • ERBB3 mutation
    |
    Gilotrif (afatinib)
    An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation (NCT03810872)
    Phase 2
    AZ-VUB
    Recruiting
    Last update posted :
    01/22/2019
    Initiation :
    06/21/2017
    Primary completion :
    12/01/2020
    Completion :
    12/01/2022
    EGFR • HER-2 • ERBB3
    |
    EGFR mutation • ERBB3 mutation
    |
    Gilotrif (afatinib) • paclitaxel